An observational study in Type 2 Diabetes, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 414 studies in Diabetes Mellitus, Type 2 with a site in France — 36 open to participants now, 41 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · France.
Among the 414 studies in Diabetes Mellitus, Type 2 with a site in France, this one is the 53rd largest by planned enrollment of the 78 observational ones that give a count, is one of 15 that started in 2024, is one of 78 observational ones, reaches primary completion later than 8 of the 40 other live ones, and was the 407th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →36 of the 414 studies in Diabetes Mellitus, Type 2 with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in France, United States, Argentina and 16 more countries
Ages 18+
Hoffmann-La Roche · Sites in France, United States, Argentina and 19 more countries
Ages 18+
Boehringer Ingelheim · Sites in France, United States, Argentina and 48 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
414 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 36 · Phase 3 143 · Phase 4 43
First in 2000; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 312 across the 336 interventional studies, 276 across the 78 observational. Of the 336 that completed or were terminated, 132 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
234 of 414 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
4 of the studies in Diabetes Mellitus, Type 2 with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
| NCT06579404University of CambridgeClosed-loop in Adults With Type 2 Diabetes | 2027-03 |
| NCT06567990Hospices Civils de LyonType 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes | 2027-05-25 |
| NCT06614101University Hospital, ToulouseStudy Enabling the Collection of Clinical Data Necessary for the Second Phase of Development of the Glycemic Measurement Device by Analysis of Exhaled Air | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 414 studies in Diabetes Mellitus, Type 2 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metformin is a drug frequently prescribed to patients with type 2 diabetes. Furthermore, diabetes can lead to micro- and macrovascular complications that may cause chronic organ failure. The presence of diabetes also increases the risk of infections. All of these factors contribute to the frequent admission of patients to the ICU who have been receiving metformin treatment in the preceding days. Acute renal failure, which is also frequently observed upon admission to the ICU, increases the risk of metformin overdose. In cases of overdose, metformin acts on several metabolic pathways that can lead to or even accelerate metabolic acidosis, sometimes severe. However, the impact on prognosis is controversial.
The role of metformin in lactic acidosis in patients treated for acute illness may be underestimated in routine practice.
This study aims to investigate the impact of prior metformin treatment on ICU survival in patients admitted to the ICU with severe lactic acidosis.
Adult patient (≥18 years) having experienced lactic acidosis (pH \<7.35 and lactate level ≥5 mmol/L) within the first 24 hours of hospitalization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Survival rates of patients with severe lactic acidosis admitted to the ICU after prior metformin treatment
Time frame: Up to 18 months
Started Nov 2024 (actual). Primary completion is estimated for May 2026, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →